Biological Information
Background Information:
Serine/threonine protein kinases RSKs contain three isoforms RSK1, RSK2 and RSK3 and act at the distal end of MAPK Signaling pathway. They are directly phosphorylated and activated by ERK1/2 in response to many growth factors, peptide hormones and neurotransmitters. RSKs have been shown to regulate apoptosis through phosphorylation and inactivation of the pro-apoptotic protein BAD, and cell cycle since the kinase Myt1 is a RSK target. RSK3 (Ribosomal protein S6 kinase 3, SK6-alpha, MAPKAPK1C) is especially interesting, because it features an additional nuclear targeting signal near its N-terminus, and can phosphorylate a variety of transcription factors (CREB, TCF/Lef, Myc, the estrogen receptor, and the Fos subunit of AP-1). GenBank XM_004469
Target Class:
Kinase
Family:
AGC
Sub Family:
Protein Ser/Thr
Protein Name:
RSK3
Protein Aliases:
90 kDa ribosomal protein S6 kinase 2|p90-RSK 2|p90RSK2|MAP kinase-activated protein kinase 1c|MAPK-activated protein kinase 1c|MAPKAP kinase 1c|MAPKAPK-1c|Ribosomal S6 kinase 3|RSK-3|pp90RSK3
Accession Number:
NM_001006932.1; NM_021135.4
UniProt Number:
Q15349
Gene Name:
RPS6KA2
Gene ID:
6196
Gene Aliases:
RSK|RSK3|HU-2|MAPKAPK1C
Target Species:
Human
Usage
Product Type:
Enzymes
Application:
Drug Discovery & Development
Storage Conditions:
1 year at -70°C
Usage disclaimer:
These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Assay Information
Assay Type:
Enzymatic
Bioassay Data
Trademark Statement:
For Research Use Only
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology